CN1265660A - 2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物 - Google Patents

2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物 Download PDF

Info

Publication number
CN1265660A
CN1265660A CN98807831A CN98807831A CN1265660A CN 1265660 A CN1265660 A CN 1265660A CN 98807831 A CN98807831 A CN 98807831A CN 98807831 A CN98807831 A CN 98807831A CN 1265660 A CN1265660 A CN 1265660A
Authority
CN
China
Prior art keywords
disorder
fluoro
compound
hydrogen
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98807831A
Other languages
English (en)
Chinese (zh)
Inventor
安东·F·J·弗里利
马克·J·马吉科扎克
帕特里西亚·A·西摩
史蒂文·H·佐恩
汉斯·罗尔马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1265660A publication Critical patent/CN1265660A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN98807831A 1997-08-15 1998-08-05 2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物 Pending CN1265660A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5576497P 1997-08-15 1997-08-15
US60/055,764 1997-08-15

Publications (1)

Publication Number Publication Date
CN1265660A true CN1265660A (zh) 2000-09-06

Family

ID=22000003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98807831A Pending CN1265660A (zh) 1997-08-15 1998-08-05 2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物

Country Status (30)

Country Link
EP (1) EP1003739A2 (fr)
JP (1) JP2002536291A (fr)
KR (1) KR20010022507A (fr)
CN (1) CN1265660A (fr)
AP (1) AP9801321A0 (fr)
AR (1) AR017019A1 (fr)
AU (1) AU8457298A (fr)
BG (1) BG104069A (fr)
BR (1) BR9811557A (fr)
CA (1) CA2297486C (fr)
CO (1) CO4960656A1 (fr)
DZ (1) DZ2583A1 (fr)
EA (1) EA200000023A1 (fr)
HR (1) HRP980441A2 (fr)
HU (1) HUP0003425A3 (fr)
ID (1) ID23803A (fr)
IL (1) IL133960A0 (fr)
IS (1) IS5336A (fr)
MA (1) MA24632A1 (fr)
NO (1) NO20000722L (fr)
OA (1) OA11286A (fr)
PA (1) PA8457001A1 (fr)
PE (1) PE106299A1 (fr)
PL (1) PL338947A1 (fr)
SK (1) SK1352000A3 (fr)
TN (1) TNSN98151A1 (fr)
TR (1) TR200000414T2 (fr)
UY (1) UY25144A1 (fr)
WO (1) WO1999009025A2 (fr)
ZA (1) ZA987304B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291925B (zh) * 2005-10-26 2013-04-10 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的哌啶-4-基哒嗪-3-胺衍生物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744539B2 (en) * 1997-10-27 2002-02-28 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
EP0953567A3 (fr) * 1998-04-29 2003-04-02 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
EP1246817B1 (fr) 1999-12-30 2004-06-23 H. Lundbeck A/S Derives de 4-phenyle-1-piperazinyle, -piperidinyle et -tetrahydropyridyle
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
EP1177792A3 (fr) 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
AU2002336273A1 (en) * 2001-03-09 2002-09-24 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
CA2497827A1 (fr) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Composes heterocycliques
WO2004108671A1 (fr) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Indoles substitues dotes d'une affinite pour le recepteur de la serotonine, leur procede de fabrication et compositions pharmaceutiques les contenant
EP2253315A1 (fr) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Dérivés d'acide alkoxypropanoique
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
WO2008128996A1 (fr) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles en tant qu'antagonistes du récepteur de la dopamine à dissociation rapide
EP2310374B1 (fr) 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. 6-(1-pipérazinyl)-pyridazines substituées comme antagonistes du récepteur 5-ht6
EP2307374B1 (fr) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Pyridines à substitution pipérazin-1-yl-trifluorométhyle en tant qu'antagonistes du récepteur de la dopamine 2 à dissociation rapide
US11266640B2 (en) * 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
US20230150980A1 (en) * 2020-04-22 2023-05-18 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (fr) * 1959-09-25 1900-01-01
ES2097341T3 (es) * 1991-07-03 1997-04-01 Upjohn Co Indoles sustituidos como farmacos para el tratamiento del sida.
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JPH08502958A (ja) * 1992-10-23 1996-04-02 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド
AU6215594A (en) * 1993-03-18 1994-10-11 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
WO1994024105A1 (fr) * 1993-04-15 1994-10-27 Merck Sharp & Dohme Limited Derives d'indole utiles comme antagonistes de la dopamine d4
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291925B (zh) * 2005-10-26 2013-04-10 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的哌啶-4-基哒嗪-3-胺衍生物

Also Published As

Publication number Publication date
DZ2583A1 (fr) 2003-02-22
AR017019A1 (es) 2001-08-22
TR200000414T2 (tr) 2000-08-21
WO1999009025A3 (fr) 1999-04-15
CO4960656A1 (es) 2000-09-25
OA11286A (en) 2003-10-22
KR20010022507A (ko) 2001-03-15
SK1352000A3 (en) 2000-08-14
BG104069A (en) 2001-05-31
IL133960A0 (en) 2001-04-30
ID23803A (id) 2000-05-11
PL338947A1 (en) 2000-12-04
JP2002536291A (ja) 2002-10-29
HUP0003425A3 (en) 2002-02-28
EP1003739A2 (fr) 2000-05-31
CA2297486C (fr) 2005-05-03
UY25144A1 (es) 2000-12-29
ZA987304B (en) 2000-02-14
PE106299A1 (es) 1999-11-02
NO20000722D0 (no) 2000-02-14
HRP980441A2 (en) 1999-04-30
AP9801321A0 (en) 2000-02-14
CA2297486A1 (fr) 1999-02-25
TNSN98151A1 (fr) 2005-03-15
MA24632A1 (fr) 1999-04-01
HUP0003425A2 (hu) 2001-10-28
PA8457001A1 (es) 2000-09-29
WO1999009025A2 (fr) 1999-02-25
IS5336A (is) 2000-01-11
NO20000722L (no) 2000-02-14
EA200000023A1 (ru) 2000-08-28
AU8457298A (en) 1999-03-08
BR9811557A (pt) 2000-08-22

Similar Documents

Publication Publication Date Title
CN1247571C (zh) 新颖的2h－哒嗪－3－酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN1064356C (zh) 新哌嗪、哌啶与1,2,5,6－四氢吡啶化合物，其制法及其药物组合物
CN1094490C (zh) 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物
CN1262678A (zh) 三唑化合物及其作为多巴胺－d3－配体的应用
CN1113236A (zh) 非肽基速激肽受体拮抗剂
CN100347164C (zh) 苯并呋喃基衍生物及其应用
CN1297438A (zh) 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮
CN1124960A (zh) 作为5-ht/a和/或5-ht2配体的吲哚衍生物
CN1265591A (zh) 化合物
CN1351591A (zh) 抗炎吲哚衍生物
CN1379777A (zh) 氨基－三唑并吡啶衍生物
CN1656082A (zh) 蛋白激酶抑制剂
CN1625556A (zh) 抗胆碱能剂,其制造方法及其作为药物的用途
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1653067A (zh) 咔唑衍生物及其作为神经肽y5受体拮抗剂的应用
CN1516580A (zh) 磺酰胺类
CN87103504A (zh) 杂环羧酰胺
CN1492863A (zh) 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
CN1050122C (zh) 苯并咪唑类,含有这些化合物的药物 组合物和它们的制备方法
CN1078469A (zh) 取代吲哚、氨杂吲哚和四氢-1H-吡咯并[2，3-c]吡啶-7-酮衍生物
CN1214017C (zh) 四唑衍生物
CN1038640A (zh) 二环碳酰胺、其制备方法及含该物质的药物组合物
CN1244577C (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1243750C (zh) 可用于治疗cns疾病的4－,5－,6－和7－吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication